When this year's Nobel Laureates were announced Monday afternoon, scientists from Erlangen University Hospital were also delighted. For one of the three eminent researchers, the British Peter Ratcliffe has links with the Huguenot city. "We have been working successfully for years with Peter Ratcliffe, especially in the field of nephrology," said Johannes Schdel, senior physician at the Medical Clinic 4 – Nephrology and Hypertensiology at Erlangen University Hospital. .
"We are extremely pleased that the Nobel Committee regards the importance of its research as such an important task and sincerely congratulates Sir Peter Rat-cliffe," added Karl Hilgers, Deputy Director of the Department of Medicine 4. As well as the work of Ratcliffe is looking to the future The Erlangen University Medical Research Foundation and the Faculty of Medicine of Erlangen-Nrnberg University have recognized: In 2013 they paid tribute to his outstanding scientific achievements with the Jakob Herz Award.
How tumors grow
This year, the Nobel Prize in Physiology or Medicine will be awarded to William Kaelin, Gregg Semenza and Peter Ratcliffe for their groundbreaking research on the characterization of oxygen detection. Thanks to the research of the three doctors, we now know how cells measure and adjust their oxygen content. The cellular and molecular mechanisms of this detection of oxygen play an important role in many diseases, such as the formation of tumors, but also in the circulation disorders of almost all organs. Medizin scientists4 investigated translational approaches to oxygen sensing mechanisms in acute and chronic renal failure, circulatory disorders of the heart, Gefen, and kidneys, and in the development of malignant kidney tumors.
The cooperation with Peter Ratcliffe began in 2004 with the appointment of the then hospital director, Kai-Uwe Eckardt, and has continued successfully ever since. The leaders of the current working group4 and Ratcliffe have been looking for longer stays in his laboratory in Oxford and have successfully continued their work in Erlangen.
Collaborative Outcomes: Scientists better understand how often a benign kidney tumor develops and can apply pharmacological stabilizers to clinically induced hypoxia-mediated transcription factors. Both are fundamentally based on the research of Peter Ratcliffe and his cooperation partners. Currently, drugs are used in clinical trials in patients with chronic renal failure. red